Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17767673 | 0.91 | TGFBR1 (0.44) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 | |
| SCHEMBL17767473 | 0.91 | TGFBR1 (0.47) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 | |
| SCHEMBL17767622 | 0.91 | TGFBR1 (0.44) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 | |
| SCHEMBL17767441 | 0.90 | TGFBR1 (0.47) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 | |
| SCHEMBL17767586 | 0.89 | TGFBR1 (0.51) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 | |
| SCHEMBL17767740 | 0.88 | TGFBR1 (0.45) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 | |
| SCHEMBL17767516 | 0.88 | TGFBR1 (0.52) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 | |
| SCHEMBL17767668 | 0.88 | TGFBR1 (0.47) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 | |
| SCHEMBL17767752 | 0.87 | TGFBR1 (0.48) | TGFBR1CSNK1DTGFBR2PDE10APDE4B | |
| SCHEMBL17767504 | 0.87 | TGFBR1 (0.44) | TGFBR1CSNK1DMAP4K4EGFRPRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207531-B | Fused imidazole derivatives as TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-05-25 | — | — | CN | claimed |
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | claimed |
| EP-3221318-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | claimed |
| WO-2016081364-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | claimed |
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
| EP-3221318-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081364-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885CSNK1D 417/4885MAP4K4 1799/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885CSNK1D 417/4885MAP4K4 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.